The Danish Organization on Randomized Trials with Clinical Outcome II evaluated 10-year clinical outcomes of patients with CAD treated with two first-generation drug-eluting stents (Cypher, Cordis and Taxus, Boston Scientific).

Design: Randomized, open-label

Patients: 2,098

Centers: Multicenter

Countries: Denmark

Results: At 10 years, 27.4% of patients in the Cypher group died vs. 26.3% in the Taxus group (HR = 1.05; 95% CI, 0.89-1.23). There were no significant differences between the groups in 10-year rates of MACE (HR = 0.96; 95% CI, 0.83-1.12) and target lesion revascularization (HR = 0.89; 95% CI, 0.72-1.11). After the first year, annual rates of MACE were steady at 2.6% in the Cypher group and 2.5% in the Taxus group. No late increase in TLR rates was observed. Acute MI primarily occurred early and there was no evidence of increased late annual rates.

Original Publications:
Galløe AM, et al. J Am Coll Cardiol. 2017;doi:10.1016/j.jacc.2016.11.055.

Healio/Cardiology News Coverage:
Long-term MACE, stent thrombosis rates steady with first-generation DES